FierceBiotech: Meissa Raises $30M to Take RSV Vaccine into the Clinic

jessica5842
Sep 26, 2019
1 min read

Updated: Jul 20, 2021

Meissa Vaccines has raised $30 million to advance a pipeline of vaccines to prevent viral respiratory infections. The series A equips Meissa to run phase 1 and 2 trials of a respiratory syncytial virus (RSV) vaccine while moving other candidates based on its synthetic biology technology toward the clinic.

Read the full article on FierceBiotech.

Recent Posts

See All

The Scientist: Nasal Vaccines Are Commercially High Risk, Perhaps High Reward

In her reporting of the nasal vaccine landscape space, Jef Akst, managing editor of The Scientist, covered Meissa's intranasal live...

Bloomberg BusinessWeek: Why Nasal Sprays Are Poised to Be the Next Weapon for Fighting Covid

Excerpt from the article: Half a Greek alphabet and two years into the pandemic, the world is coming to terms with the notion that...

The Washington Post: The Next Leap in Coronavirus Vaccine Development Could Be a Nasal Spray

Excerpt from WaPo ------- As the omicron variant of the coronavirus moved lightning-fast around the world, it revealed an unsettling...

Opmerkingen

Het is niet meer mogelijk om opmerkingen te plaatsen bij deze post. Neem contact op met de website-eigenaar voor meer info.